Q4 2024 EPS Estimates for MiMedx Group, Inc. (NASDAQ:MDXG) Lowered by HC Wainwright

MiMedx Group, Inc. (NASDAQ:MDXG) – Research analysts at HC Wainwright reduced their Q4 2024 earnings estimates for MiMedx Group in a report issued on Wednesday, May 1st. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings of $0.11 per share for the quarter, down from their previous forecast of $0.12. HC Wainwright has a “Buy” rating and a $11.00 price objective on the stock. The consensus estimate for MiMedx Group’s current full-year earnings is $0.33 per share.

MiMedx Group (NASDAQ:MDXG) last posted its quarterly earnings data on Wednesday, February 28th. The company reported $0.04 EPS for the quarter, missing the consensus estimate of $0.08 by ($0.04). The firm had revenue of $86.83 million for the quarter, compared to analysts’ expectations of $85.58 million. MiMedx Group had a return on equity of 64.61% and a net margin of 18.63%.

A number of other analysts have also issued reports on MDXG. Lake Street Capital assumed coverage on shares of MiMedx Group in a research note on Thursday, March 7th. They set a “buy” rating and a $12.00 target price for the company. Mizuho boosted their target price on shares of MiMedx Group from $13.00 to $14.00 and gave the company a “buy” rating in a research note on Friday, March 1st. Four analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, MiMedx Group currently has an average rating of “Buy” and a consensus price target of $12.25.

MiMedx Group Stock Up 2.6 %

Shares of MDXG opened at $7.50 on Thursday. The firm has a market capitalization of $1.11 billion, a P/E ratio of 17.14 and a beta of 1.44. MiMedx Group has a 12-month low of $4.47 and a 12-month high of $9.27. The company has a current ratio of 3.57, a quick ratio of 3.11 and a debt-to-equity ratio of 0.34. The firm has a fifty day moving average price of $7.38 and a 200-day moving average price of $7.56.

Hedge Funds Weigh In On MiMedx Group

A number of large investors have recently added to or reduced their stakes in the company. Optimist Retirement Group LLC bought a new position in MiMedx Group in the fourth quarter worth about $177,000. Cannell Capital LLC raised its holdings in MiMedx Group by 9.1% in the fourth quarter. Cannell Capital LLC now owns 2,480,969 shares of the company’s stock worth $21,758,000 after purchasing an additional 207,207 shares in the last quarter. Campbell & CO Investment Adviser LLC raised its holdings in MiMedx Group by 26.9% in the fourth quarter. Campbell & CO Investment Adviser LLC now owns 261,604 shares of the company’s stock worth $2,294,000 after purchasing an additional 55,435 shares in the last quarter. Hillsdale Investment Management Inc. increased its holdings in shares of MiMedx Group by 69.2% during the fourth quarter. Hillsdale Investment Management Inc. now owns 447,900 shares of the company’s stock valued at $3,928,000 after acquiring an additional 183,141 shares in the last quarter. Finally, Jump Financial LLC increased its holdings in shares of MiMedx Group by 8.7% during the fourth quarter. Jump Financial LLC now owns 97,260 shares of the company’s stock valued at $853,000 after acquiring an additional 7,753 shares in the last quarter. 79.15% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, CAO William Frank Iv Hulse sold 20,381 shares of the company’s stock in a transaction dated Wednesday, March 13th. The shares were sold at an average price of $7.95, for a total value of $162,028.95. Following the completion of the sale, the chief accounting officer now directly owns 479,959 shares of the company’s stock, valued at $3,815,674.05. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other MiMedx Group news, COO Ricci S. Whitlow sold 15,271 shares of the business’s stock in a transaction dated Tuesday, February 20th. The shares were sold at an average price of $8.01, for a total value of $122,320.71. Following the completion of the transaction, the chief operating officer now directly owns 401,050 shares in the company, valued at $3,212,410.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO William Frank Iv Hulse sold 20,381 shares of the business’s stock in a transaction dated Wednesday, March 13th. The stock was sold at an average price of $7.95, for a total transaction of $162,028.95. Following the completion of the transaction, the chief accounting officer now owns 479,959 shares of the company’s stock, valued at $3,815,674.05. The disclosure for this sale can be found here. Insiders sold a total of 51,145 shares of company stock valued at $409,378 over the last three months. 19.90% of the stock is owned by company insiders.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.